Abstract:Muhammad Asad Faruqi, 1 Malik M Khurram S Khan, 1 David M Mannino 1, 2 1 University of Kentucky College of Medicine, Lexington, KY, USA; 2 COPD Foundation, Miami, FL, USA Correspondence: David M Mannino, Department of Medicine, University of Kentucky College of Medicine, 800 Rose Street, Lexington, KY, 40536, USA, Email Ensifentrine is a novel inhalational phosphodiesterase (PDE)3 and PDE4 inhibitor which improves bronchodilation and decreases inflammatory markers by acting locally on the bronchial tissue, with minimal systemic effects. Both preclinical and clinical trials have demonstrated benefits of this therapy, including improvement in lung function and reduction in exacerbations. This therapy is currently under review by the US Food and Drug Administration with a decision expected in 2024. Keywords: chronic obstructive pulmonary disease, therapy, phosphodiesterase inhibitor Chronic obstructive pulmonary disease (COPD) is a progressive inflammatory disorder of the respiratory system which is characterized by irreversible airflow obstruction, remodeling of the airways and acute exacerbations leading to lung function decline, progressive dyspnea, and cough. 1 Treatment of COPD is aimed towards reducing symptoms like shortness of breath and mucous production, preventing flare-ups, slowing disease progression and improving survival. COPD therapies involve both non-pharmacological and pharmacological interventions. Some patients on maximal therapies, including inhaled bronchodilators and steroids and oral phosphodiesterase 4 (PDE4) inhibitors, can still be symptomatic. Thus, new therapies are needed that can improve lung function and airway inflammation when used in addition to existing therapies. 2,3 In addition, current inhaled therapies may not be tolerated by all patients. Thus, therapies with alternative mechanisms of action are needed. In this article, we review the literature available on ensifentrine, a novel phosphodiesterase inhibitor that has the potential to be an add-on therapy for patients with COPD. Ensifentrine (RPL554) is a novel drug that works by dual inhibition of phosphodiesterase (PDE) 3 and 4 enzymes (PDE3, PDE4) and is designed to be delivered via inhalation. 4 Inhibitors of PDE3 and PDE4 target multiple respiratory functions at the cellular and tissue level (Figure 1). PDE3 regulates cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) levels in the airway smooth muscles, which mediates bronchial tone. 5 PDE4 regulates cAMP levels in the airway cells associated with inflammation and is involved in activation of these cells. 6 PDE4 inhibitors can also activate the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) and improve bronchial epithelial cell ciliary movements. 7 Evidence has recently emerged that dual inhibition of PDE3 and PDE4 enzymes results in a synergistic effect of decreased inflammation and improved bronchodilation as both iso-forms of PDE are expressed in the inflammatory cells and airway smooth muscles. 8,9 This article explores the evidence to date regarding ensifentrine as a novel therapeutic option for the treatment of COPD. Figure 1 Combined inhibition of phosphodiesterase (PDE) 3 and PDE4 has additive and synergistic anti-inflammatory and bronchodilatory effects versus inhibition of either PDE3 or PDE4 alone. Furthermore, it increases mucociliary clearance. In red, the main PDE involved in the activity of the specific cell. With permission, from Current Opinion in Pharmacology. Notes : Reprinted from Current Opinion in Pharmacology, Volume 56, Matera MG, Cazzola M, Page C, Prospects for COPD treatment. pages 74–84, copyright 2021, with permission from Elsevier. 3 Several in vitro and in vivo studies evaluated the effect of PDE3/4 inhibitors on airway smooth muscles and degree of inflammation. One study investigated the effects of ensifentrine (RPL554) on the tone of isolated human airway smooth muscles and its synergistic actions when used in conjunction with other bronchodilators including muscarinic antagonists and beta-adrenergic agonists. The study demonstrated that ensifentrine caused relaxation of the bronchial smooth muscles and had a synergistic effect when used with muscarinic antagonists. 10 Ensifentrine's effect on bronchial epithelial cell cultures obtained from normal and Cystic Fibrosis (CF) patients with F508del genotype has also been evaluated. 11 It stimulates CFTR-dependent chloride ion secretion across bronchial epithelial cells and increases cilia beat frequency in primary human bronchial epithelial cells. It also decreases the production of monocyte chemoattractant protein-1 and granulocyte monocyte colony -Abstract Truncated-

"Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis." M. Kolb, B. Crestani and T.M. Maher. Eur Respir Rev 2023; 32: 220206.

The Potentially Therapeutic Role of EPAC in Curbing the Process of Idiopathic Pulmonary Fibrosis Via Differential Cellular Pathways

Phosphodiesterase 4 inhibition reduces lung fibrosis following targeted type II alveolar epithelial cell injury

Discover Natural Compounds As Potential Phosphodiesterase-4B Inhibitors Via Computational Approaches

Expression and Action of Phosphodiesterase 4B in Bleomycin-Induced Pulmonary Fibrosis in Mice

A Novel, Pan-PDE Inhibitor Exerts Anti-Fibrotic Effects in Human Lung Fibroblasts via Inhibition of TGF-β Signaling and Activation of cAMP/PKA Signaling

Potential of phosphodiesterase 4B inhibitors in the treatment of interstitial lung disease associated with autoimmune diseases

Perspectives of PDE Inhibitor on Treating Idiopathic Pulmonary Fibrosis

The need for inhaled phosphodiesterase inhibitors in chronic obstructive pulmonary disease

Mangostanin Derivatives as Novel and Orally Active Phosphodiesterase 4 Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis with Improved Safety

Perspectives on Ensifentrine and Its Therapeutic Potential in the Treatment of COPD: Evidence to Date

PDE4B inhibition by nerandomilast: Effects on lung fibrosis and transcriptome in fibrotic rats and on biomarkers in human lung epithelial cells

Pharmacological Inhibition of Epac1 Protects against Pulmonary Fibrosis by Blocking FoxO3a Neddylation

Advances In The Development Of Phosphodiesterase-4 Inhibitors

Lead optimization and mode-of-action elucidation for novel antifibrotics

Discovery of Selective PDE1 Inhibitors with Anti-pulmonary Fibrosis Effects by Targeting the Metal Pocket

Phosphodiesterase 7 as a therapeutic target - Where are we now?

Phosphodiesterase-4 Inhibition in Parkinson's Disease: Molecular Insights and Therapeutic Potential

PDE4D: A Multipurpose Pharmacological Target

The Sphingosine Kinase 1 Inhibitor, PF543, Mitigates Pulmonary Fibrosis by Reducing Lung Epithelial Cell mtDNA Damage and Recruitment of Fibrogenic Monocytes

Phosphodiesterase 4 is overexpressed in human keloids and its inhibition reduces fibroblast activation and skin fibrosis